Education
About Us
Working with TipRanks
Follow Us
Cyfuse Biomedical K.K. (JP:4892)
:4892
4892 Stock Chart & Stats
Day’s Range― - ―
52-Week Range¥430.00 - ¥1,412.00
Previous CloseN/A
Volume38.50K
Average Volume (3M)190.69K
Market Cap
¥5.52B
Enterprise Value¥3.78B
Total Cash (Recent Filing)¥3.05B
Total Debt (Recent Filing)¥852.00M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 14, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.90
Shares Outstanding8,373,600
10 Day Avg. Volume102,470
30 Day Avg. Volume190,693
Financial Highlights & Ratios
PEG Ratio-0.91
Price to Book (P/B)2.40
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥891.00Price Target Upside35.20% Upside
Rating ConsensusHold
Number of Analyst Covering0
4892 FAQ
What was Cyfuse Biomedical K.K.’s price range in the past 12 months?
Cyfuse Biomedical K.K. lowest stock price was ¥430.00 and its highest was ¥1412.00 in the past 12 months.
What is Cyfuse Biomedical K.K.’s market cap?
Cyfuse Biomedical K.K.’s market cap is ¥5.52B.
When is Cyfuse Biomedical K.K.’s upcoming earnings report date?
Cyfuse Biomedical K.K.’s upcoming earnings report date is Aug 14, 2025 which is in 21 days.
How were Cyfuse Biomedical K.K.’s earnings last quarter?
Cyfuse Biomedical K.K. released its earnings results on May 15, 2025. The company reported -¥19.9 earnings per share for the quarter, missing the consensus estimate of N/A by -¥19.9.
Is Cyfuse Biomedical K.K. overvalued?
According to Wall Street analysts Cyfuse Biomedical K.K.’s price is currently Undervalued.
Does Cyfuse Biomedical K.K. pay dividends?
Cyfuse Biomedical K.K. does not currently pay dividends.
What is Cyfuse Biomedical K.K.’s EPS estimate?
Cyfuse Biomedical K.K.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyfuse Biomedical K.K. have?
Cyfuse Biomedical K.K. has 8,373,600 shares outstanding.
What happened to Cyfuse Biomedical K.K.’s price movement after its last earnings report?
Cyfuse Biomedical K.K. reported an EPS of -¥19.9 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.002%.
Which hedge fund is a major shareholder of Cyfuse Biomedical K.K.?
Currently, no hedge funds are holding shares in JP:4892
Company Description
Cyfuse Biomedical K.K.
Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells. Cyfuse Biomedical K.K. was incorporated in 2010 and is based in Tokyo, Japan.
Technical Analysis
Solasia Pharma KK
―
Morishita Jintan Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Medrx Co., Ltd.
―
Modalis Therapeutics Corporation
―